Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Nortel Networks (NT) -- Ignore unavailable to you. Want to Upgrade?

To: t2 who wrote (12178)	1/2/2002 1:05:54 PM
From: telecomguy	Respond to of 14638

who knows what will happen. That's the beauty of the market i suppose. Regards biotech, weakness could be just low volume related .. also biotechs go up & down by 2 to 5 % every day for no reason...one issue may be the imclone rejection...there seems to be higher incidence of FDA rejecting the drug approval applications..... One thing about the pharma sector, there is still lots of EXTREMELY well funded large pharmas who are capable of buying out many of the emerging biotechs to replenish their pipleline. Unlike the telco sector where the incumbents (PTT's) who used to have lots of cash are now up to their ying-yang with debt due to IP buildout and 3G bet (that was the ultimate stupidity in terms of how much these PTT's shelled out for the 3G spectrum).